Zomedica Corp. (ZOM) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.53 M

Shareholding (Mar 2025)

FII

0.86%

Held by 12 FIIs

DII

92.66%

Held by 17 DIIs

Promoter

0.00%

How big is Zomedica Corp.?

22-Jun-2025

As of Jun 18, Zomedica Corp. has a market capitalization of 41.65 million, with net sales of 27.53 million and a net profit of -101.63 million over the latest four quarters. As of December 2024, the company reported shareholder's funds of 195.66 million and total assets of 207.36 million.

What does Zomedica Corp. do?

22-Jun-2025

Zomedica Corp. is a veterinary diagnostic and pharmaceutical company focused on companion animals, with recent quarterly net sales of $7 million and a net loss of $64 million. The company has a market cap of $41.65 million and no dividend yield.

Who are in the management team of Zomedica Corp.?

22-Jun-2025

As of March 2022, Zomedica Corp.'s management team includes Chairman Jeffrey Rowe, CEO Robert Cohen, Chief Medical Officer Dr. William MacArthur, and several independent directors, including Dr. Jane Eagleson and Dr. Johnny Powers, among others. They oversee the company's strategic direction and operations.

Is Zomedica Corp. overvalued or undervalued?

20-Sep-2025

As of March 1, 2022, Zomedica Corp. is rated as "risky" and appears overvalued with key metrics indicating a lack of profitability, including a Price to Book Value of 0.33 and a P/E ratio of -2.71, suggesting significant risk compared to its peers.

Is Zomedica Corp. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Zomedica Corp.'s technical trend is neutral with mixed signals, showing a shift from mildly bullish to sideways, while underperforming the S&P 500 with a 1-week return of -26.68% and a 1-year return of -34.04%.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 79 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.46

Return on Equity

-23.35%

Price to Book

0.63

Revenue and Profits:

Net Sales:

7 Million

(Quarterly Results - Jun 2025)

Net Profit:

-7 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

89.17%

6 Months

157.95%

1 Year

-13.36%

2 Years

-33.24%

3 Years

-44.39%

4 Years

-65.61%

5 Years

-35.33%

Zomedica Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Zomedica Corp. technically bullish or bearish?

As of 12 September 2025, the technical trend for Zomedica Corp. has changed from mildly bullish to sideways. The current stance is neutral, with mixed signals across various indicators. The weekly MACD and KST are mildly bullish, while the monthly KST is bearish. The RSI is bullish on the weekly timeframe but shows no signal monthly. Moving averages indicate a mildly bearish trend on the daily timeframe. Additionally, the Bollinger Bands reflect a mildly bullish stance weekly but a mildly bearish one monthly. In terms of performance, Zomedica has underperformed the S&P 500 across multiple periods, with a 1-week return of -26.68% compared to the S&P's 1.05%, and a 1-year return of -34.04% versus the S&P's 17.14%....

Is Zomedica Corp. overvalued or undervalued?

As of 1 March 2022, Zomedica Corp. has moved from a "does not qualify" rating to "risky." The company appears to be overvalued given its current metrics. Key valuation ratios include a Price to Book Value of 0.33, an EV to EBIT of 0.58, and an EV to EBITDA of 0.77, all indicating a lack of profitability and financial stability. In comparison to its peers, Zomedica's P/E ratio is -2.71, while Fusion Pharmaceuticals, Inc. has a P/E of -17.58, and Gossamer Bio, Inc. has a P/E of -4.38, suggesting that Zomedica is not the worst performer in its group but still reflects significant risk. The recent stock performance comparison with the S&P 500 is not available, yet the overall valuation metrics reinforce the notion of Zomedica being overvalued in its current state....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

96.59%

EBIT Growth (5y)

-184.27%

EBIT to Interest (avg)

-27.69

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.48

Sales to Capital Employed (avg)

0.13

Tax Ratio

0.44%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

11.06%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.33

EV to EBIT

0.58

EV to EBITDA

0.77

EV to Capital Employed

-0.28

EV to Sales

-0.70

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-22.48%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bullish

Bearish

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

No Trend

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 7 Schemes (6.48%)

Foreign Institutions

Held by 12 Foreign Institutions (0.86%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 14.75% vs 1.67% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 69.04% vs -359.62% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.00",
          "val2": "6.10",
          "chgp": "14.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.10",
          "val2": "-7.10",
          "chgp": "14.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-16.00",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.40",
          "val2": "-23.90",
          "chgp": "69.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,153.80%",
          "val2": "-1,475.00%",
          "chgp": "32.12%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 8.33% vs 33.33% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -36.23% vs -102.94% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "27.30",
          "val2": "25.20",
          "chgp": "8.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-27.00",
          "val2": "-25.30",
          "chgp": "-6.72%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.20",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-16.00",
          "val2": "-11.70",
          "chgp": "-36.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-47.00",
          "val2": "-34.50",
          "chgp": "-36.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,283.80%",
          "val2": "-1,254.30%",
          "chgp": "-2.95%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

7.00

6.10

14.75%

Operating Profit (PBDIT) excl Other Income

-6.10

-7.10

14.08%

Interest

0.00

Exceptional Items

0.00

-16.00

100.00%

Consolidate Net Profit

-7.40

-23.90

69.04%

Operating Profit Margin (Excl OI)

-1,153.80%

-1,475.00%

32.12%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 14.75% vs 1.67% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 69.04% vs -359.62% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

27.30

25.20

8.33%

Operating Profit (PBDIT) excl Other Income

-27.00

-25.30

-6.72%

Interest

0.00

0.20

-100.00%

Exceptional Items

-16.00

-11.70

-36.75%

Consolidate Net Profit

-47.00

-34.50

-36.23%

Operating Profit Margin (Excl OI)

-1,283.80%

-1,254.30%

-2.95%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 8.33% vs 33.33% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -36.23% vs -102.94% in Dec 2023

All Annual Results

Company CV

About Zomedica Corp.

Zomedica Corp.

Pharmaceuticals & Biotechnology

Zomedica Corp., formerly Zomedica Pharmaceuticals Corp., is a development stage veterinary diagnostic and pharmaceutical company. The Company is engaged in developing products for companion animals, such as canine, feline, and equine by focusing on needs of clinical veterinarians. It is focused on developing three diagnostic platforms, a Bulk Acoustic Wave sensor-based veterinary point-of-care diagnostic platform for performing immunodiagnostic testing, a Raman spectroscopy-based point-of-care diagnostic platform for the detection of pathogens, and liquid biopsy assays for the detection of cancer, along with related consumables. The Company’s TRUFORMA product candidate is an investigational device being developed as a point-of-care biosensor platform. ZM-020 is its diagnostic platform being developed to screen for a range of pathogens in companion animal feces, urine, respiratory, and dermatological samples. It is developing ZM-017 as a canine cancer liquid biopsy platform.

Company Coordinates

Company Details

100 Phoenix Drive, Suite 180 , ANN ARBOR MI : 48108

Tel: 1 734 3692555

http://www.zomedica.com/

Registrar Details

Zomedica Corp.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Zomedica Corp.?

Watch in Real-Time

What does Zomedica Corp. do?

Who are in the management team of Zomedica Corp.?

Is Zomedica Corp. overvalued or undervalued?

Is Zomedica Corp. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Zomedica Corp. technically bullish or bearish?

Is Zomedica Corp. overvalued or undervalued?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Zomedica Corp.

Company Coordinates